GILD Gilead Sciences Inc.

65.57
-1.78  -3%
Previous Close 67.35
Open 66.8
Price To Book 3.71
Market Cap 84822637959
Shares 1,293,619,612
Volume 8,237,933
Short Ratio
Av. Daily Volume 7,292,015

SEC filingsSee all SEC filings

  1. 8-K - Current report 181226163
  2. CT ORDER - Confidential treatment order 181170224
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163125
  4. 8-K - Current report 181138993
  5. CT ORDER - Confidential treatment order 181091089

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 2 24-week endpoint due 4Q 2018.
Tirabrutinib (GS-4059)
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 1Q 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 data due 2Q 2019.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 2 data 2Q 2018.
GS-9674
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to be completed 2Q 2019.
GS-5734
Ebola
Phase 3 data due 2Q 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 enrollment to be completed 4Q 2018.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 data due 2Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 2 data released September 6, 2018. Primary endpoint met.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 data released May 30, 2018 - primary endpoint met.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data due 2Q 2019.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 enrollment to be completed 4Q 2018.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 initiated November 2016. Enrollment to be completed 2H 2019.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)
Phase 2 enrollment to be completed 4Q 2018.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial initiated 4Q 2018. Phase 1 updated data at ASH December 2018 noted 69% CR or incomplete hematological recovery (CRi).
Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 2 trial to be initiated 4Q 2018.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 2 enrollment to be completed 3Q 2018.
KTE-C19 (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 trial to be initiated 4Q 2018.
KTE-C19 (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 2 48-week data due 4Q 2019.
Selonsertib + GS-9674 combo
Nonalcoholic steatohepatitis (NASH)
Phase 3 data due 2Q 2019.
GS-9131
HIV
Phase 3 enrollment to be completed 2H 2019.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. Stocks That Fell to 3-Year Lows in the Week of Dec. 14
  2. 3 Biotechs Gilead Sciences Could Buy in March
  3. Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus
  4. AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
  5. 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
  6. Today's Research Reports on Trending Tickers: Axovant Sciences and Gilead Sciences
  7. The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
  8. Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals
  9. Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
  10. The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
  11. Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
  12. Understanding Seattle Genetics’ Operational Performance
  13. What Seattle Genetics’ Bottom-Line Trend Indicates
  14. How’s Seattle Genetics Positioned?
  15. New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James
  16. 7 Stocks That Can Lead The Market Long Term
  17. The 10 Best Marijuana Stocks to Buy in 2019
  18. 4 Biotech Stocks Investors Can Add to Their Portfolio in 2019
  19. See what the IHS Markit Score report has to say about Gilead Sciences Inc.
  20. Why CRSP Stock Has Added Layers of Risk

SEC Filings

  1. 8-K - Current report 181226163
  2. CT ORDER - Confidential treatment order 181170224
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163125
  4. 8-K - Current report 181138993
  5. CT ORDER - Confidential treatment order 181091089
  6. 8-K - Current report 181075868
  7. CT ORDER - Confidential treatment order 181071622
  8. CT ORDER - Confidential treatment order 181023985
  9. 8-K - Current report 18997825
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18994917